Mainz Biomed NV Financials

Mainz Biomed NV (MYNZ) reported $537K in total revenue for fiscal year 2025. This represents a -39.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Mainz Biomed NV (MYNZ) revenue declined by 39.9% year-over-year, from $894K to $537K in fiscal year 2025.

No, Mainz Biomed NV (MYNZ) reported a net income of -$16.2M in fiscal year 2025, with a net profit margin of -3018.3%.

Mainz Biomed NV (MYNZ) reported diluted earnings per share of $-2.70 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Mainz Biomed NV (MYNZ) had EBITDA of -$15.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Mainz Biomed NV (MYNZ) had a gross margin of 72.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

Mainz Biomed NV (MYNZ) had an operating margin of -3005.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

Mainz Biomed NV (MYNZ) had a net profit margin of -3018.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Mainz Biomed NV (MYNZ) has a return on equity of -2526.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Mainz Biomed NV (MYNZ) generated -$11.0M in free cash flow during fiscal year 2025. This represents a 37.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Mainz Biomed NV (MYNZ) generated -$11.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Mainz Biomed NV (MYNZ) had $5.3M in total assets as of fiscal year 2025, including both current and long-term assets.

Mainz Biomed NV (MYNZ) invested $1K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Mainz Biomed NV (MYNZ) invested $4.9M in research and development during fiscal year 2025.

Mainz Biomed NV (MYNZ) had 10M shares outstanding as of fiscal year 2025.

Mainz Biomed NV (MYNZ) had a current ratio of 0.90 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

Mainz Biomed NV (MYNZ) had a debt-to-equity ratio of 7.30 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Mainz Biomed NV (MYNZ) had a return on assets of -304.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Based on fiscal year 2025 data, Mainz Biomed NV (MYNZ) had $889K in cash against an annual operating cash burn of $11.0M. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Mainz Biomed NV (MYNZ) has an Altman Z-Score of -36.22, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Mainz Biomed NV (MYNZ) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Mainz Biomed NV (MYNZ) has an earnings quality ratio of 0.68x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Mainz Biomed NV (MYNZ) has an interest coverage ratio of -43.2x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.